Payment overview · 2025
General Payments
$498.41
22 reported records · 9 companies
Healthcare provider profile · identity verified
Marcella Wheeler, CFNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BEAUMONT, TX · NPI 1487600227
Verified facts
What the public records show
CMS Open Payments records show Marcella Wheeler, CFNP received $498.41 in general payments during 2025 across 22 reported records.
AstraZeneca Pharmaceuticals LP accounted for 38.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $192.49 | 38.6% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $58.66 | 11.8% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $55.95 | 11.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.85 | 9.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.41 | 9.3% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $33.12 | 6.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $26.15 | 5.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.44 | 4.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.34 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $498.41 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $139.81 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $92.39 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $55.95 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $47.85 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $46.41 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $42.99 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $40.58 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $39.71 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $33.12 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $26.15 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $26.15 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $14.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 74 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 63 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
68 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
74 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 457 | 148 |
| Atorvastatin Calcium | Atorvastatin Calcium | 426 | 127 |
| Amlodipine Besylate | Amlodipine Besylate | 413 | 127 |
| Tizanidine Hcl | Tizanidine Hcl | 313 | 92 |
| Gabapentin | Gabapentin | 312 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 296 | 83 |
| Lisinopril | Lisinopril | 288 | 81 |
| Furosemide | Furosemide | 283 | 90 |
| Omeprazole | Omeprazole | 262 | 71 |
| Montelukast Sodium | Montelukast Sodium | 240 | 75 |
| Metformin Hcl | Metformin Hcl | 220 | 70 |
| Methylprednisolone | Methylprednisolone | 200 | 158 |
| Losartan Potassium | Losartan Potassium | 197 | 67 |
| Potassium Chloride | Potassium Chloride | 193 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 188 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 187 | 57 |
| Alprazolam | Alprazolam | 175 | 41 |
| Tramadol Hcl | Tramadol Hcl | 171 | 71 |
| Simvastatin | Simvastatin | 164 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 161 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 151 | 49 |
| Trazodone Hcl | Trazodone Hcl | 146 | 49 |
| Meloxicam | Meloxicam | 140 | 49 |
| Sertraline Hcl | Sertraline Hcl | 139 | 41 |
| Carvedilol | Carvedilol | 128 | 35 |
| Ozempic | Semaglutide | 121 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 113 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 106 | 44 |
| Lorazepam | Lorazepam | 103 | 22 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 100 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 29 |
| Azithromycin | Azithromycin | 97 | 79 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 42 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 26 |
| Eliquis | Apixaban | 74 | 21 |
| Amoxicillin | Amoxicillin | 71 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 69 | 58 |
| Buspirone Hcl | Buspirone Hcl | 68 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 68 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 23 |
| Glimepiride | Glimepiride | 67 | 17 |
| Pregabalin | Pregabalin | 65 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 19 |
| Farxiga | Dapagliflozin Propanediol | 63 | 17 |
| Bupropion Xl | Bupropion Hcl | 62 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 13 |
| Estradiol | Estradiol | 60 | 26 |
| Spironolactone | Spironolactone | 60 | 13 |
| Meclizine Hcl | Meclizine Hcl | 58 | 26 |
| Allopurinol | Allopurinol | 57 | 18 |
| Mupirocin | Mupirocin | 57 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 50 | 11 |
| Nystatin | Nystatin | 50 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 49 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 48 | 14 |
| Alendronate Sodium | Alendronate Sodium | 47 | 17 |
| Clonazepam | Clonazepam | 47 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 15 |
| Donepezil Hcl | Donepezil Hcl | 43 | 16 |
| Fluconazole | Fluconazole | 42 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 13 |
| Clonidine Hcl | Clonidine Hcl | 40 | 11 |
| Ibuprofen | Ibuprofen | 39 | 12 |
| Lovastatin | Lovastatin | 39 | suppressed |
| Atenolol | Atenolol | 38 | 12 |
| Celecoxib | Celecoxib | 38 | 14 |
| Famotidine | Famotidine | 38 | 12 |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 14 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Glipizide Er | Glipizide | 35 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 30 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 18 |
| Trulicity | Dulaglutide | 26 | suppressed |
| Prednisone | Prednisone | 25 | 13 |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 16 |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 19 |
| Linzess | Linaclotide | 21 | 11 |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 17 |
| Metolazone | Metolazone | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 15 |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Klor-Con 10 | Potassium Chloride | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Tri-Sprintec | Norgestimate-Ethinyl Estradiol | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Valproic Acid | Valproic Acid | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $498.41 · 22 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, ELIQUIS, FARXIGA, GVOKE HYPOPEN, JARDIANCE, NURTEC ODT, REZDIFFRA, SHINGRIX, TRELEGY ELLIPTA, VRAYLAR, Veozah | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error